Charles River Earnings: Stock Soars as Elliott Investment Management Launches Strategic Review

Narrow-moat Charles River Laboratories announced an agreement with Elliott Investment Management to add four new directors to its board and enhance value creation through a strategic review to optimize the company’s performance and drive efficiencies. Investors were spooked last month by the US Food and Drug Administration’s announcement to reduce animal testing for preclinical safety assessments. However, management provided more details on how it plans to advance hybrid study designs by complementing traditional animal studies with technologies such as artificial intelligence, and it will continue to expand its nonanimal platforms to address evolving regulations. Shares soared almost 19% after the earnings update, as investor confidence increased in the firm’s long-term prospects.